Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02039947
Title	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	GlaxoSmithKline
Indications	melanoma
Therapies	Dabrafenib + Trametinib
Age Groups:	adult
Covered Countries	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUS